



WHAT STARTS HERE CHANGES THE WORLD

The iQ Group Global grows momentum with senior promotions

Media Release

24 August 2016

Unique and innovative pharmaceutical industry leader The iQ Group Global continues to gather momentum with two recent promotions within their executive team - officially appointing Jimena Hurtado as General Manager of their Clinical Research Corporation (CRC) business and Lei Xu as Director of their Asia Pacific Business Unit.

Jimena has been promoted after a short, yet successful period as Acting General Manager of CRC. With a robust background including over 17 years' experience in pharmaceutical development, sales, and human resource management, Jimena is heading the CRC team in driving all deliverables on the corporate objectives.

CEO of iQ Group Global Dr George Syrmalis says her appointment will create a strong force to lead and execute the strategy and ensure continuous growth of the business

"Her extensive knowledge of the industry combined with her passion and commitment for the CRC Brand has resulted in the execution of pioneering strategies that continue to grow business, develop its presence in the market, and differentiate it as a strategic medical affairs business partner to the pharmaceutical industry," he said.

Jimena describes her approach as, "strategic and methodical, ensuring the CRC team achieves their business goals as planned."

Lei Xu has already proven to be a remarkable asset to the iQ Group Global, from initially joining the team in 2014 as Head of APAC Investor Relations, her undeniable leadership and accountability characteristic have formulated effective growth trajectories in her sector.

"Lei Xu uses solidarity and cross functionality to lead project, making her a key contributor to our company's growth," Dr Syrmalis said.

The two new appointments strengthen the well-established iQ Group Global leadership team, reinforcing their commitment to fostering a high performance culture by recruiting and retaining highly skilled and passionate staff.

"We may be young but we are strongly positioned to challenge our competitors in the pharmaceutical industry supported by our bedrock values," Dr Syrmalis said.

"Continued success will aid in bridging the gap between capital and science to create the medicines of the future."

ENDS.

Notes for journalists:

For additional commentary please contact Jose Verbeek at WE Buchan on jverbeek@buchanwe.com.au or phone (02) 9237 2807

About The iQ Group Global

iQ Group Global supports, promotes and grows the Australian biotechnology sector. They are the trusted partner to their investors, biotechnology and global pharmaceutical clients, adding value through their ability to find, invest, partner, grow and divest early stage biotechnology assets. At every step in the journey, the expertise of The iQ Group Global



WHAT STARTS HERE CHANGES THE WORLD

delivers advice, experience and support designed to add value to the core biotechnology investment.

www.theiqgroupglobal.com.au

About CRC

Clinical Research Corporation (CRC) Pty Ltd is a wholly owned subsidiary of iQnovate Ltd, a globally listed life science organisation and member of the iQ Group Global. CRC Pty Ltd is an organisation that provides strategic medical affairs services to the pharmaceutical industry throughout the entire drug development life cycle, from preclinical to clinical and through to registration, reimbursement and commercialisation.

www.crcaustralia.com